[Secondary prevention of stroke with antiplatelet drugs]

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Patients with transient ischemic attack (TIA) or ischemic stroke have a significant risk of recurrent stroke, particularly in the period immediately following the initial event.
• The risk of stroke recurrence within the first year ranges from 10% to 15%.
• In patients without a cardiac source of embolism, acetylsalicylic acid (ASA) is established for reducing stroke risk.

Purpose of the Study:

• To review the efficacy of antiplatelet therapies in secondary stroke prevention.
• To highlight the comparative effectiveness of aspirin and clopidogrel.
• To discuss ongoing clinical trials investigating combination antiplatelet therapies for secondary stroke prevention.

Main Methods:

• Review of clinical trial data and established medical literature on antiplatelet therapy.
• Analysis of relative risk reduction for vascular events associated with aspirin.
• Comparison of aspirin and clopidogrel efficacy in high-risk patient populations.

Main Results:

• Aspirin (ASA) provides an 18% relative risk reduction for recurrent vascular events and a 13% reduction for stroke.
• Clopidogrel demonstrates superiority over ASA in patients with high recurrence risk due to comorbidities or multiple risk factors.
• Current research focuses on combination antiplatelet therapies to further improve outcomes.

Conclusions:

• Antiplatelet therapy, particularly aspirin, is crucial for secondary stroke prevention.
• Clopidogrel offers improved efficacy for specific high-risk patient groups.
• Ongoing large-scale clinical trials are evaluating the benefits and safety of combination antiplatelet strategies compared to monotherapy.